Canada Markets closed

Mind Medicine (MindMed) Inc. (MNMD)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
1.8500-0.1400 (-7.04%)
At close: 04:00PM EST
1.8800 +0.03 (+1.62%)
After hours: 07:58PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close1.9900
Open1.9900
Bid1.8500 x 3200
Ask1.8800 x 3200
Day's Range1.8200 - 2.0000
52 Week Range1.8200 - 5.7700
Volume4,108,758
Avg. Volume3,613,272
Market Cap418.692M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateMar. 30, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.50
  • CNW Group

    MindMed to Participate at the Benzinga Global Small Cap Conference

    Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that MindMed's Chief Executive Officer, Robert Barrow, will provide a corporate update and the Company's management will participate in one-on-one investor meetings at the Benzinga Global Small Cap Conference to be held virtually on December 8-9, 2021.

  • CNW Group

    MindMed to Present at H.C. Wainwright 2nd Annual Psychedelics Conference

    Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ) (the "Company"), a leading biotech company developing psychedelic-inspired therapies, today announced that MindMed's Chief Executive Officer, Robert Barrow, will participate in a panel and Company's management will participate in one-on-one investor meetings at the virtual H.C. Wainwright 2nd Annual Psychedelics Conference to be held on Monday, December 6, 2021.

  • CNW Group

    MindMed and Liechti Lab publish first human data on the interacting effects of an SSRI and psilocybin

    Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (NEO: MMED), (DE: MMQ); (the "Company"), a leading biotech company developing psychedelic-inspired therapies, is pleased to announce the publication of the first data on the interaction of the selective serotonin uptake inhibitor (SSRI) escitalopram with the acute response to psilocybin in humans. The publication resulted from a randomized, double-blind, placebo-controlled, crossover pharmacology study in healthy volunteers conducted by the University